Somatostatin (SST), also known as somatotropin release-inhibiting factor (SRIF), is a cyclic peptide hormone with potent inhibitory regulatory effects throughout the body. First identified in 1973 as a hypothalamic factor that suppresses growth hormone (GH) secretion, somatostatin is now recognized as a multifunctional peptide involved in numerous endocrine, gastrointestinal, and neurological processes. Two biologically active isoforms exist: SST-14, a 14-amino-acid peptide predominantly found in the brain, and SST-28, a 28-amino-acid peptide primarily localized within the gastrointestinal (GI) tract. Both isoforms are generated through post-translational processing of the common precursor preprosomatostatin.

Mechanism of Action and Receptor Signaling

Somatostatin mediates its biological functions through five G protein-coupled receptor subtypes (SST1–SST5), which are widely distributed throughout the central nervous system and peripheral tissues. Activation of these receptors couples to inhibitory G proteins (Gi), resulting in reduced intracellular cyclic AMP (cAMP) production, decreased calcium influx, and enhanced potassium efflux. These signaling events ultimately suppress hormone secretion and cellular activity. Among the receptor subtypes, SST2 and SST5 play particularly important roles in the treatment of pituitary adenomas and neuroendocrine tumors (NETs), making them key therapeutic targets.

Clinical Significance

The clinical application of native somatostatin is limited by its very short plasma half-life of approximately 1–3 minutes. Consequently, several long-acting synthetic analogs, including octreotide, lanreotide, and pasireotide, have been developed for therapeutic use. These compounds are widely employed in the treatment of acromegaly and a variety of neuroendocrine tumors, such as carcinoid tumors and insulinomas, where they effectively suppress hormone hypersecretion and inhibit tumor progression. In addition, the SST2 receptor serves as a major molecular target for peptide-based radiopharmaceuticals used in diagnostic imaging and peptide receptor radionuclide therapy (PRRT), making it an important component of precision medicine for neuroendocrine malignancies.